All (n=30) | TN (n=16) | HR+ (n=14) | |
Clinical characteristics | |||
Age, median (range) | 51 (27–68) | 54.5 (27–68) | 49 (36–68) |
Race, % (n) | |||
White | 83% (25) | 88% (14) | 79% (11) |
Black | 10% (3) | 6% (1) | 14% (2) |
Unknown | 7% (2) | 6% (1) | 7% (1) |
Ethnicity, % (n) | |||
Non-Hispanic | 93% (28) | 94% (15) | 93% (13) |
Hispanic | 7% (2) | 6% (1) | 7% (1) |
ECOG PS, % (n) | |||
0 | 57% (17) | 56% (9) | 57% (8) |
1 | 40% (12) | 38% (6) | 43% (6) |
2 | 3% (1) | 6% (1) | 0% (0) |
Visceral disease | 93% (28) | 88% (14) | 100% (14) |
Prior therapies for MBC | |||
Total prior therapies, median (range) | 1 (0–6) | 1 (0–6) | 2 (0–4) |
Endocrine therapy, median (range) | 0 (0–4) | N/A | 1 (0–3) |
Chemotherapy, median (range) | 1 (0–5) | 1 (0–5) | 0 (0–2) |
First line for MBC, % (n) | 17% (7) | 31% (5) | 7% (1) |
ECOG, Eastern Cooperative Oncology Group; HR+, hormone receptor-positive endocrine-refractory ; MBC, metastatic breast cancer ; N/A, not available; PS, performance status; TN, triple negative .